Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Simvastatin suppresses dexamethasone-induced secretion of plasminogen activator inhibitor-1 in human bone marrow adipocytes ; volume:12 ; number:1 ; day:27 ; month:4 ; year:2011 ; pages:1-7 ; date:12.2011
BMC musculoskeletal disorders ; 12, Heft 1 (27.4.2011), 1-7, 12.2011
- Urheber
-
Sakamoto, Kazutaka
- Beteiligte Personen und Organisationen
-
Ōsaki, Makoto
Hozumi, Akira
Goto, Hisataka
Fukushima, Tatsuya
Baba, Hideo
Shindo, Hiroyuki
SpringerLink (Online service)
- DOI
-
10.1186/1471-2474-12-82
- URN
-
urn:nbn:de:1111-2016043019257
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sakamoto, Kazutaka
- Ōsaki, Makoto
- Hozumi, Akira
- Goto, Hisataka
- Fukushima, Tatsuya
- Baba, Hideo
- Shindo, Hiroyuki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Die Bedeutung der Plasminogenaktivatoren tissue-type-plasminogen activator und urokinase-type plasminogen activator für den Ischämie-Reperfusionsschaden
Bone Marrow Plasminogen Activator in Malignant Disease
Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration
Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
Urokinase-type plasminogen activator receptor in vascular calcification
Influence of delivery on plasminogen activator inhibitor activity
Plasminogen Activator Release by Oral Contraceptives and Exercise
Isolation and Properties of Human Vascular Plasminogen Activator
Purification and Some Properties of Tissue Plasminogen Activator
Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Die Bedeutung der Plasminogenaktivatoren tissue-type-plasminogen activator und urokinase-type plasminogen activator für den Ischämie-Reperfusionsschaden
Bone Marrow Plasminogen Activator in Malignant Disease
Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration
Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
Urokinase-type plasminogen activator receptor in vascular calcification
Influence of delivery on plasminogen activator inhibitor activity
Plasminogen Activator Release by Oral Contraceptives and Exercise
Isolation and Properties of Human Vascular Plasminogen Activator
Purification and Some Properties of Tissue Plasminogen Activator
Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)
Quantification of urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) mRNA in breast cancer tissue
Die Bedeutung der Plasminogenaktivatoren tissue-type-plasminogen activator und urokinase-type plasminogen activator für den Ischämie-Reperfusionsschaden
Bone Marrow Plasminogen Activator in Malignant Disease
Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration
Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy
Urokinase-type plasminogen activator receptor in vascular calcification
Influence of delivery on plasminogen activator inhibitor activity
Plasminogen Activator Release by Oral Contraceptives and Exercise
Isolation and Properties of Human Vascular Plasminogen Activator
Purification and Some Properties of Tissue Plasminogen Activator
Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers
Analysis of Urokinase-type Plasminogen Activator (uPA), Plasminogen Activator Inhibitor Type-1 (PAI-1), and Urokinase Plasminogen Activator Receptor (uPAR) Protein Expression by Immunohistochemistry in Triple-Negative Breast Cancer (TNBC)